Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Pain. 2020 Nov 21;22(5):498–508. doi: 10.1016/j.jpain.2020.11.004

Figure 5. TACAN AS-ODN does not attenuate mechanical hyperalgesia associated with oxaliplatin chemotherapy-induced peripheral neuropathy (CIPN).

Figure 5.

Rats were treated intrathecally with TACAN AS- (120 μg/20 μL) or MM- (120 μg/20 μL) ODN, once a day, for three consecutive days. On the fourth day, approximately 24 h after the last intrathecal administration of ODNs, (t(5)=0.5218; p=0.6241, for the TACAN MM- ODN-treated group and, t(5)=7.593; ###p=0.0006, for the TACAN AS-ODN-treated group, when the mechanical nociceptive threshold is compared before and approximately 24 hours after the third intrathecal injection of ODN; paired Student’s t-test), rats received an intravenous injection of oxaliplatin (2 mg/kg). The mechanical nociceptive threshold was evaluated before the 1st dose of ODNs, before oxaliplatin injection, and then 30min and 1, 7 14, 21 and 28 days after oxaliplatin. TACAN AS-ODN did not attenuate oxaliplatin-induced mechanical hyperalgesia at any time point evaluated (F(7,70)=5.874, *p<0.0136, when the TACAN AS-ODN- is compared with TACAN MM-ODN-treated group before intravenous oxaliplatin; p=0.5868 when the TACAN AS-ODN- is compared with TACAN MM-ODN-treated group after oxaliplatin; two-way repeated-measures ANOVA followed by Bonferroni’s multiple comparison test). n=6 per group.